Streetbeat News

Stock Prices

MKTX

Barclays analyst Benjamin Budish has downgraded MarketAxess Holdings (MKTX) from Overweight to Equal-Weight while increasing the price target from $246 to $291.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:24 pm

ADMQ

VANI

XXII

Insiders at Vivani Medical, 22nd Century Group, and ADM Endeavors have recently made notable stock purchases. Vivani Medical's Director Gregg Williams bought 6,200 shares at $1.07 each, while the company reported a wider-than-expected quarterly loss in November. 22nd Century Group's CEO Lawrence Firestone acquired 100,000 shares at $0.17 each following the sale of its hemp/cannabis operations. ADM Endeavors' CEO Marc Johnson purchased 125,500 shares at $0.04 each, with the stock rising about 30% over the past five days.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 1:20 pm

HARP

LMDX

SPR

LumiraDx Limited (NASDAQ:LMDX) shares plummeted over 30% in pre-market trading due to the announcement that its securities will be suspended from Nasdaq trading starting January 9th. Other stocks experienced significant movement in pre-market trading, with Harpoon Therapeutics, Inc. (NASDAQ:HARP) seeing a near 100% gain after reports of Merck's acquisition talks, and Spirit AeroSystems Holdings, Inc. (NYSE:SPR) dropping over 16% following the FAA's grounding of certain Boeing 737 Max 9 aircraft.

Portfolio Pulse from Avi Kapoor

January 08, 2024 | 1:20 pm

BLFS

BioLife Solutions announced preliminary Q4 revenue of $32.7M, which is below the estimated $33.82M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:20 pm

OKYO

HC Wainwright & Co. analyst Yi Chen has reaffirmed a Buy rating on OKYO Pharma (NASDAQ:OKYO) and increased the price target from $4 to $5.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:18 pm

BAC

C

JPM

WFC

U.S. banking giants are facing a challenging fourth quarter with a rise in bad debts and the impact of higher interest rates. Non-performing loans at the four largest U.S. banks have increased by nearly $6 billion, reaching $24.4 billion. The banks are also expected to take a one-time charge due to a special assessment by the FDIC related to the failures of Silicon Valley Bank and Signature. Despite these challenges, bank shares have risen by 20% since October, buoyed by the Fed's signals of halting interest rate hikes. JPMorgan Chase & Co. (JPM), Bank of America Corp (BAC), Wells Fargo & Co (WFC), and Citigroup Inc. (C) are set to report earnings on Jan. 12.

Portfolio Pulse from Benzinga Neuro

January 08, 2024 | 1:17 pm

DASH

DoorDash shares have risen following an upgrade from analysts at Jefferies, who changed their rating to Buy and set a price target of $130 for the stock.

Portfolio Pulse from Luke J Jacobi

January 08, 2024 | 1:17 pm

VERA

Vera Therapeutics, Inc. (NASDAQ:VERA) will host an R&D day on January 25, 2024, to present week 72 data from the Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy (IgAN). The event will feature experts Dr. Richard Lafayette and Dr. Jonathan Barratt. The ORIGIN trial met its primary endpoint, showing significant proteinuria reductions and eGFR stabilization. Atacicept is a recombinant fusion protein targeting autoimmune diseases, and the trial's results suggest potential for best-in-class treatment.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:16 pm

BROS

Dutch Bros Inc. expanded significantly in Q4 2023, opening 37 new shops, with 32 being company-operated. Throughout 2023, they opened 159 new shops, 146 of which were company-operated. The company anticipates opening an additional 150-165 shops in FY24.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:15 pm

BLNK

Needham analyst Chris Pierce upgraded Blink Charging (NASDAQ:BLNK) from Hold to Buy and set a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:15 pm